Explore

TrendlineTrendline
Sino Biopharmaceutical Licenses Six Oncology Programs to Boehringer Ingelheim in Multi-Billion Dollar Deal

Sino Biopharmaceutical Licenses Six Oncology Programs to Boehringer Ingelheim in Multi-Billion Dollar Deal

Sino Biopharmaceutical Licenses Six Oncology Programs to Boehringer Ingelheim in Multi-Billion Dollar Deal
TrendlineTrendline
US Biotech Startups Advised to Focus on Novel Technologies to Compete with China

US Biotech Startups Advised to Focus on Novel Technologies to Compete with China

US Biotech Startups Advised to Focus on Novel Technologies to Compete with China
TrendlineTrendline
Moderna and Merck Advance Personalized mRNA Cancer Vaccine for Melanoma, Eyeing Regulatory Filing

Moderna and Merck Advance Personalized mRNA Cancer Vaccine for Melanoma, Eyeing Regulatory Filing

Moderna and Merck Advance Personalized mRNA Cancer Vaccine for Melanoma, Eyeing Regulatory Filing
TrendlineTrendline
China's 30-Day Drug Approval Process Attracts U.S. Biotech First-in-Human Trials

China's 30-Day Drug Approval Process Attracts U.S. Biotech First-in-Human Trials

China's 30-Day Drug Approval Process Attracts U.S. Biotech First-in-Human Trials
TrendlineTrendline
Boehringer Ingelheim Secures Six Chinese Cancer Programs in Deal Valued Up to $7 Billion

Boehringer Ingelheim Secures Six Chinese Cancer Programs in Deal Valued Up to $7 Billion

Boehringer Ingelheim Secures Six Chinese Cancer Programs in Deal Valued Up to $7 Billion
TrendlineTrendline
Boehringer Ingelheim Expands Cancer Drug Collaboration with Sino Biopharmaceutical, Investing Up to $7.4 Billion

Boehringer Ingelheim Expands Cancer Drug Collaboration with Sino Biopharmaceutical, Investing Up to $7.4 Billion

Boehringer Ingelheim Expands Cancer Drug Collaboration with Sino Biopharmaceutical, Investing Up to $7.4 Billion
TrendlineTrendline
Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements
TrendlineTrendline
U.S. Treasury Proposes Expanded Outbound Investment Security Regulations Under COINS Act

U.S. Treasury Proposes Expanded Outbound Investment Security Regulations Under COINS Act

U.S. Treasury Proposes Expanded Outbound Investment Security Regulations Under COINS Act
TrendlineTrendline
Mondego Bio Initiates First-in-Human Study of MB-388 for Cancer Immunotherapy Resistance

Mondego Bio Initiates First-in-Human Study of MB-388 for Cancer Immunotherapy Resistance

Mondego Bio Initiates First-in-Human Study of MB-388 for Cancer Immunotherapy Resistance
SB NationSB Nation
Tsai partner on sports as an asset class and bigger business behind Nets

Tsai partner on sports as an asset class and bigger business behind Nets

When Joe Tsai bought a 49% stake in the Brooklyn Nets in 2017, he and longtime investment partner Ollie Weisberg saw value in the NBA’s “limited” supply of teams and the growing market for live sports — starting in Brooklyn. Opportunities to buy into the league are rare, let alone to own one of two […]
TrendlineTrendline
Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline

Caldera Therapeutics Reports Positive Phase 1a Data for CLD-423 and Expands Immunology Pipeline
TrendlineTrendline
Eli Lilly, Novo Nordisk, and Pfizer Intensify Competition in China's Weight-Loss Drug Market at CIIE

Eli Lilly, Novo Nordisk, and Pfizer Intensify Competition in China's Weight-Loss Drug Market at CIIE

Eli Lilly, Novo Nordisk, and Pfizer Intensify Competition in China's Weight-Loss Drug Market at CIIE